Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Tuberculosis vaccines: present and future.

Minassian AM, McShane H.

Expert Rev Respir Med. 2008 Dec;2(6):721-38. doi: 10.1586/17476348.2.6.721.

PMID:
20477235
2.

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.

Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, Keyser A, Moyo S, Brittain N, Lawrie A, Gelderbloem S, Veldsman A, Hatherill M, Hawkridge A, Hill AV, Hussey GD, Mahomed H, McShane H, Hanekom WA.

Eur J Immunol. 2010 Jan;40(1):279-90. doi: 10.1002/eji.200939754. Erratum in: Eur J Immunol. 2011 May;41(5):1501.

3.

Autocrine production of beta-chemokines protects CMV-Specific CD4 T cells from HIV infection.

Casazza JP, Brenchley JM, Hill BJ, Ayana R, Ambrozak D, Roederer M, Douek DC, Betts MR, Koup RA.

PLoS Pathog. 2009 Oct;5(10):e1000646. doi: 10.1371/journal.ppat.1000646. Epub 2009 Oct 30.

4.

Trends in tuberculosis incidence and their determinants in 134 countries.

Dye C, Lönnroth K, Jaramillo E, Williams BG, Raviglione M.

Bull World Health Organ. 2009 Sep;87(9):683-91.

5.

Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review.

Korenromp EL, Williams BG, Schmid GP, Dye C.

PLoS One. 2009 Jun 17;4(6):e5950. doi: 10.1371/journal.pone.0005950.

6.

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.

Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Alder N, Van Wijgerden J, Hill AV, Gleeson FV, Davies RJ, Pasvol G, McShane H.

Am J Respir Crit Care Med. 2009 Apr 15;179(8):724-33. doi: 10.1164/rccm.200809-1486OC. Epub 2009 Jan 16.

7.

A comparison of IFNgamma detection methods used in tuberculosis vaccine trials.

Beveridge NE, Fletcher HA, Hughes J, Pathan AA, Scriba TJ, Minassian A, Sander CR, Whelan KT, Dockrell HM, Hill AV, Hanekom WA, McShane H.

Tuberculosis (Edinb). 2008 Nov;88(6):631-40. doi: 10.1016/j.tube.2008.06.005. Epub 2008 Sep 17.

PMID:
18801705
8.

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries DJ, Donkor SA, Fletcher HA, Hammond AS, Lienhardt C, Adegbola RA, McShane H, Hill AV.

PLoS One. 2008 Aug 13;3(8):e2921. doi: 10.1371/journal.pone.0002921. Erratum in: PLoS One. 2011;6(2). doi:10.1371/annotation/5284a0b6-62a9-484e-80a4-a08c59b3b17c.

9.

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.

Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, Lang T, Veldsman A, Hatherill M, Merwe Lv, Fletcher HA, Mahomed H, Hill AV, Hanekom WA, Hussey GD, McShane H.

J Infect Dis. 2008 Aug 15;198(4):544-52. doi: 10.1086/590185. Erratum in: J Infect Dis. 2011 Jul;204(1):176.

10.

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.

Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Beveridge NE, Whelan KT, Hill AV, McShane H.

PLoS One. 2007 Oct 24;2(10):e1052. Erratum in: PLoS One. 2011;6(2).doi:10.1371/annotation/71208a01-eb32-469c-96ab-8d5e3c497fce.

11.

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.

Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, Asher TE, Ambrozak DR, Precopio ML, Scheinberg P, Alder NC, Roederer M, Koup RA, Douek DC, Hill AV, McShane H.

Eur J Immunol. 2007 Nov;37(11):3089-100. Erratum in: Eur J Immunol. 2011 May;41(5):1501.

12.

Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control.

Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E, Raviglion M.

Expert Rev Anti Infect Ther. 2007 Oct;5(5):857-71. Review.

PMID:
17914919
13.

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.

Dorrell L, Williams P, Suttill A, Brown D, Roberts J, Conlon C, Hanke T, McMichael A.

Vaccine. 2007 Apr 30;25(17):3277-83. Epub 2007 Jan 11.

PMID:
17257714
14.
15.

Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells.

Loré K, Smed-Sörensen A, Vasudevan J, Mascola JR, Koup RA.

J Exp Med. 2005 Jun 20;201(12):2023-33.

16.

Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.

Harrer E, Bäuerle M, Ferstl B, Chaplin P, Petzold B, Mateo L, Handley A, Tzatzaris M, Vollmar J, Bergmann S, Rittmaier M, Eismann K, Müller S, Kalden JR, Spriewald B, Willbold D, Harrer T.

Antivir Ther. 2005;10(2):285-300.

PMID:
15865223
17.

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV.

Nat Med. 2004 Nov;10(11):1240-4. Epub 2004 Oct 24. Erratum in: Nat Med. 2004 Dec;10(12):1397.

PMID:
15502839
18.

T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis.

Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, Kuruppu J, Yazdani J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA.

J Virol. 2004 Feb;78(3):1160-8.

19.

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals.

Cosma A, Nagaraj R, Bühler S, Hinkula J, Busch DH, Sutter G, Goebel FD, Erfle V.

Vaccine. 2003 Dec 8;22(1):21-9.

PMID:
14604567
20.

HIV preferentially infects HIV-specific CD4+ T cells.

Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, Grossman Z, Dybul M, Oxenius A, Price DA, Connors M, Koup RA.

Nature. 2002 May 2;417(6884):95-8.

PMID:
11986671

Supplemental Content

Support Center